Blood metabolomic measures associate with present and future glycemic control in type 2 diabetes.

Leen M ‘t Hart, Nicole Vogelzangs, Dennis O Mook-Kanamori, Adela Brahimaj, Jana Nano, Amber AWA van der Heijden, Ko Willems van Dijk, Roderick C Slieter, Ewout Steyerberg, M Arfan Ikram, Marian Beekman, Dorret I Boomsma, Cornelia M van Duijn, P Eline Slagboom, Coen DA Stehouwer, Casper G Schalkwijk, Ilja CW Arts, Jacqueline M Dekker, Abbas Dehghan, Taulant Muka, Carla JH van der Kallen, Giel Nijpels, Marleen van Greevenbroek

The Journal of Clinical Endocrinology & Metabolism
Endocrine Society

Submitted: May 29, 2018
Accepted: July 30, 2018
First Online: August 02, 2018

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising references to, products or publications do not imply endorsement of that product or publication.
Metabolomics and glycemic control in diabetes

**Blood metabolomic measures associate with present and future glycemic control in type 2 diabetes.**


1 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands
2 Leiden University Medical Center, Department of Biomedical Data Sciences, Section of Molecular Epidemiology, Leiden, the Netherlands
3 VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands
4 Maastricht University, Department of Epidemiology, Cardiovascular Research Institute Maastricht (CARIM) & Maastricht Centre for Systems Biology (MaCSBio), Maastricht, the Netherlands
5 Leiden University Medical Center, Department of Clinical Epidemiology, Leiden, the Netherlands
6 Leiden University Medical Center, Department of Public Health and Primary Care, Leiden, the Netherlands
7 Erasmus Medical Center, Department of Epidemiology, Rotterdam, the Netherlands
8 Helmholtz Zentrum Munich, German Research Center for Environmental Health, Institute of Epidemiology, Munich, Germany
9 German Center for Diabetes Research (DZD), Munich, Germany
10 VU University Medical Center, Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands
11 Leiden University Medical Center, Einthoven Laboratory for Experimental Vascular Medicine, Leiden, the Netherlands
12 Leiden University Medical Center, Leiden, Department of Human Genetics, Leiden, the Netherlands
13 Leiden University Medical Center, Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
14 Leiden University Medical Center, Leiden, Department of Biomedical Data Sciences, Leiden, the Netherlands
15 Vrije Universiteit, Department of Biological Psychology, Amsterdam, the Netherlands
16 Maastricht University, School for Cardiovascular Diseases (CARIM), Maastricht University, Maastricht, the Netherlands
17 Maastricht University Medical Center, Department of Internal Medicine, Maastricht, the Netherlands
18 Department of Biostatistics and Epidemiology, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK

Received 29 May 2018. Accepted 30 July 2018.

**Objective** We studied in people with type 2 diabetes whether blood metabolomic measures are associated with insufficient glycemic control and if this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles associate with initiation of insulin therapy.

**Methods** One-hundred-and-sixty-two metabolomic measures were analyzed using a NMR-based method in people with type 2 diabetes from four cohort studies (n=2641) and one
replication cohort (n=395). Linear and logistic regression with adjustment for potential confounders followed by meta-analyses was done to analyze associations with HbA1c levels, six glucose-lowering drug categories, and insulin initiation during seven year follow-up (n=698).

**Results** After Bonferroni correction twenty-six measures were associated with insufficient glycemic control (HbA1c>53 mmol/mol). The strongest association was with glutamine (OR=0.66 (95%CI 0.61;0.73), P=7.6x10^-19). In addition when compared to treatment naïve patients thirty-one metabolomic measures were associated with glucose-lowering drugs use (representing various metabolite categories, all P<3.1x10^-4). In drug-stratified analyses, associations with insufficient glycemic control were only mildly affected by different glucose-lowering drugs. Five of the 26 metabolomic measures (ApoA1 and M-HDL subclasses) were also associated with insulin initiation during follow-up in both discovery and replication. With the strongest association observed for M-HDL-CE (OR=0.54 (95%CI=0.42;0.71); P=4.5x10^-6).

**Conclusion** In conclusion blood metabolomic measures were associated with present and future glycemic control and may thus provide relevant cues to identify those at increased risk of treatment failure.

In a metabolomics study of persons with type 2 diabetes we found 26 metabolomic measures associated with insufficient glycemic control. Five also associated with insulin initiation during follow-up.

**Introduction** Type 2 diabetes is a very heterogeneous disease, which is also reflected in the heterogeneity in response to glucose-lowering treatment. Previously, we showed distinct trajectories of glucose control in people with type 2 diabetes, with most achieving good glycemic control (1). People with type 2 diabetes who are not treated optimally are at increased risk of developing diabetes-related complications (1,2). As such, there is a growing interest to discover factors associated with poor treatment response to facilitate personalized therapeutics.

Recent technologic advances allow simultaneous detection of a wide range of metabolites in biological samples to gain information on multiple pathways relevant for a person’s metabolic state (3). The rapid developments in technology to determine a blood metabolomic profile in combination with highly standardized, reproducible and affordable measurements may all facilitate introduction of metabolomics in daily clinical practice aiming to advance the personalization and effectiveness of treatment of type 2 diabetes.

Blood metabolomic measures such as the branched chain amino acids (BCAAs), alpha-hydroxybutyrate, 2-aminoadipic acid, various lipids and other metabolites have been associated with risk of type 2 diabetes (4-6). Changes in the blood metabolomic profile may reflect early changes in the disease process of type 2 diabetes but may also influence the progression. As such, metabolomics might be a useful tool in early identification and stratification of those at increased risk of type 2 diabetes and to gain knowledge about disease etiology and progression (4). While previous findings show that metabolomic profiles add information on top of well-known clinical risk factors in prediction of developing type 2 diabetes (7), only few studies have investigated their utility in assessment of treatment response and disease progression. These studies mostly investigated which metabolites respond to initiation of glucose-lowering drugs (8,9), however, often limited to only a single drug and in small cohorts.

In search of better markers for successful treatment response, we herein use metabolomics data of four independent type 2 diabetes cohorts from the Netherlands. The metabolomic measures investigated belong to several classes including: amino acids,
glycolysis measures, ketone bodies and fatty acids, as well as the lipid concentrations and compositions of 14 lipoprotein subclasses. We assess the cross-sectional and glucose-lowering drug-stratified associations of these metabolomic measures with glycemic control. Three cohorts provide data to examine the prospective association of metabolomic measures with diabetes progression.

Materials and Methods

Type 2 diabetes cohorts
Data of type 2 diabetes patients (n=2641) from four different cohorts from the Netherlands were used; the Hoorn Diabetes Care System cohort study (DCS, n=995)(10), the Maastricht study (Maastricht, n=848)(11), the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM, n=134)(12) and the Netherlands Epidemiology of Obesity study (NEO, n=664)(13). Prospective data from follow-up visits were available in two studies (DCS and CODAM, n=698) and in an independent replication study, the Rotterdam study (n=395)(14). All studies were conducted in accordance with the declaration of Helsinki, approved by the relevant local medical ethics committees and participants gave written informed consent before entering the study. Detailed cohort descriptions and study characteristics are described below and shown in table 1 and Supplemental tables 1-5.

The Hoorn Diabetes Care System cohort study (DCS).
The DCS provides routine diabetes care to patients living in the West-Friesland region (10). Patients visit the DCS research center annually during which blood is drawn in the fasting state for routine biochemistry. Furthermore, the patients get a full medical exam, advice about their health and treatment and receive education on their disease during their annual visits to the DCS research center. In addition, patients are invited to join our research and biobanking studies (n=5000+). From the DCS biobank we included a random cross-sectional sample for which a baseline plasma sample and yearly follow-up data were available (n=750). For case-control analyses this sample was supplemented with subjects selected for the inability to reach the glycemic target (HbA1c>53 mmol/mol) and/or suffering from diabetic complications (n=245). For the prospective study we used data from 596 patients from the random sample who weren’t using insulin at the time of blood sampling for metabolomics and for which follow-up data was available. Follow-up time was 7 (interquartile range 6-7) years. Hemoglobin A1c (HbA1c) determination was based on the turbidimetric inhibition immunoassay for hemolysed whole EDTA blood (Cobas c501, Roche Diagnostics, Mannheim, Germany).

The CODAM study
The CODAM (Cohort on Diabetes and Atherosclerosis Maastricht) study was started in 1999. The baseline measurements of CODAM (n=574) were obtained between 1999 and 2002 (12). CODAM is a prospective, observational cohort. The general aim of CODAM is to investigate the effects of glucose metabolism, lipids, lifestyle and genetics on (development of) type 2 diabetes and its cardiovascular complications (with focus on etiological relations). For the current study we included all subjects with type 2 diabetes for which a baseline plasma sample and Hemoglobin A1c (HbA1c) level was available (n=134). For the prospective studies we used data from 102 patients who were not using insulin at the time of blood sampling for metabolomics and for whom follow-up data was available. Average follow-up time was 7 years (interquartile range 6.9–7.1) (15). HbA1c determination was based on ion-exchange high-performance liquid chromatography (HPLC).

The Maastricht study
The Maastricht Study is an extensive phenotyping study that focuses on the etiology of type 2 diabetes, its classic complications (cardiovascular disease, nephropathy, neuropathy and
retinopathy), and its emerging comorbidities. The study represents a population-based cohort of 10,000 individuals that is enriched with type 2 diabetes participants. A detailed description of the study design can be found in: Schram et al. (11). For the current study we included all subjects with type 2 diabetes for which a baseline plasma sample was available at the time of metabolite quantification (n=848). One subject for whom detailed medication data were not available was excluded from analyses involving medication data. HbA1c determination was based on ion-exchange high-performance liquid chromatography (HPLC).

The NEO study
The Netherlands Epidemiology of Obesity (NEO) study: The NEO was designed for extensive phenotyping to investigate pathways that lead to obesity-related diseases (13). The NEO study is a population-based, prospective cohort study that includes 6,671 individuals aged 45–65 years, with an oversampling of individuals with overweight or obesity. For those with type 2 diabetes at baseline plasma samples were measured in the present study (n=664). HbA1c was measured using HPLC boronate affinity chromatography.

The Rotterdam study
The Rotterdam Study is a prospective population-based cohort study in Ommoord, a district of Rotterdam, the Netherlands. The design of the Rotterdam Study has been described in more detail elsewhere (14). Briefly, in 1989 all residents within the well-defined study area aged 55 years or older were invited to participate of whom 78% (7983 out of 10275) agreed. The first examination took place from 1990 to 1993, after which, follow-up examinations were conducted every 3-5 years. This metabolomics study was based on plasma samples and baseline data collected during the third visit (1997-1999). Follow-up data were from the fourth visit (2002-2004). For the current study we used 395 subjects with type 2 diabetes who were not using insulin at the third study visit.

Glucose-lowering drug use
We defined six different treatment groups: (1) glucose-lowering drug treatment naive (‘No-Meds’); (2) metformin monotherapy (‘Mef’); (3) sulfonylurea monotherapy (‘SU’); (4) Metf and SU combined (‘Metf+SU’); (5) insulin therapy, either with or without oral glucose-lowering drugs (‘Insulin’) and (6) use of oral glucose-lowering medication other than Metf and/or SU (‘Other’). ‘Other’ consisted mainly of thiazolidinediones (TZD) users, either with or without Metf and/or SU. Clinical characteristics, medication use and the number of subjects per stratum per cohort are given in Supplemental Tables 1-3.

Metabolomic measurements
Fasted EDTA plasma samples were analyzed in a single experimental setup on a high-throughput nuclear magnetic resonance (NMR) platform as described previously (www.nightingalehealth.com)(16,17). In total 162 metabolomic measures and or derived composite scores (n=12) were assessed which represent a broad molecular signature of systemic metabolism. This includes metabolites such as amino acids, glycolytic intermediates, fatty acids and ketone bodies and 141 other metabolomic measures such as mono- and polyunsaturated fatty acids, glycerides, proteins as well as lipid concentrations and compositions of 14 lipoprotein subclasses (Supplemental Table 6). A heatmap showing the correlation structure of the metabolomic measures in the DCS cohort is shown in supplemental figure 1. These metabolomic measures were all in absolute molar concentration units.

Statistical analysis
Metabolomic measures in the different study samples were normalized using z-scaling after natural logarithmic transformation of the raw levels (ln(measure+1)) as suggested by the
manufacturer and to facilitate cross-cohort comparisons. HbA1c levels were logarithmically transformed (ln) prior to the analyses in each of the cohorts.

In each of the cohorts linear and logistic per-measure regression models with adjustment for potential confounders (based on literature) were used to study continuous and binary outcomes, respectively. Only complete cases were used. Details are described below for each of the main analyses. Bonferroni correction was applied on all analyses to account for multiple testing (162 tests, $\alpha \leq 3.1 \times 10^{-4}$). We have chosen to use Bonferroni correction based on the number of metabolic measures tested but not to correct for the number of tests performed. Because of the high correlation between metabolites (~40 independent signals) this equates for the stratified analyses (n=5) to an almost similar cut-off (5x40=200 tests, $p \leq 2.5 \times 10^{-4}$ versus $3.1 \times 10^{-4}$). For the other endpoints (glycemic control and insulin initiation) where we performed less tests such a cut-off would be too strict. Therefore, for uniformity and readability of the manuscript we chose to use one significance threshold throughout the paper based on the number of metabolomic measures ($p \leq 3.1 \times 10^{-4}$). SPSS v23.0 and R v3.4.0 were used for data analysis. Random effect meta-analyses were used to combine the results of the different study samples using the R package meta (Meta v4.3-2)(18).

**Association between metabolomic measures and HbA1c.**

The associations between metabolomic measures (main independent variables) and HbA1c levels (outcome) at the time of blood draw were examined using linear regression models ($n_{total}$=2641). Logistic regression was used to analyze associations of metabolomic measures with insufficient glycemic control defined as having an HbA1c above 53 mmol/mol (7%) at the time of the blood drawing. Two models were used: model 1 included as covariates age, sex, statin use (yes/no) and use of other lipid lowering medication (yes/no). In model 2 we additionally adjusted for BMI, use of oral glucose-lowering medication (yes/no), insulin use (yes/no) and duration of diabetes at the time of blood draw. Based on previous evidence we examined the influence of the six different treatment regimens on the association between metabolomic measures and HbA1c in drug stratified analyses. To examine differences between those without medication and other treatment groups interaction analyses were performed (treatment_group*metabolite). Sensitivity analyses were performed by excluding subjects with less than one year of diabetes and those only treated with a diet and in analyses stratified by sex.

**Associations between glucose-lowering drug use and metabolomic measures**

In a cross-sectional design we applied linear regression analyses to examine the association between different types of glucose-lowering medication (main independent variable) and metabolomic measures (outcomes). Separate analyses for each treatment group with the treatment naive group as the reference were used for each cohort separately. Analyses were restricted to DCS, Maastricht and NEO cohorts because the numbers per stratum were too small in CODAM. Age, sex, statin use (yes/no) and use of other lipid lowering medication were added as covariates (model 1). In model 2 we additionally adjusted for BMI, duration of diabetes, HbA1c, fasting glucose and estimated glomerular filtration rate (eGFR) at the time of blood draw. eGFR was estimated using the CKD-EPI equation(19).

**Association between metabolomic measures and initiation of insulin therapy**

The metabolomic measures that were identified as cross-sectionally associated with HbA1c >53 mmol/mol in the previous analyses were included in the current analyses. The association between these baseline metabolomic measures (main independent variables) and initiation of insulin therapy during the follow-up period (outcome) were examined with logistic regression in the prospective cohorts. For these analyses we only included people who did not use insulin at the time of blood sampling (n=698). Baseline values of age, sex, BMI, statin use, other lipid lowering use (model 1) and diabetes duration, SU use, metformin
use, other diabetes medication use, HbA1c and fasting glucose (model 2) were included as covariates. For replication in the Rotterdam study we used a slightly different model that included age, sex, BMI, lipid lowering medication use, oral glucose-lowering medication use and fasting glucose, as not all covariates were available.

Sensitivity analyses: It is known that for various reasons people who should use insulin because of prolonged elevated HbA1c levels aren’t using this drug. Therefore, we performed sensitivity analyses in the largest prospective cohort, DCS. Propensity scores for insulin use at baseline were calculated using graded boosting as implemented in the \textit{gbm} package in R (v2.1.3)(20). Sex, age, BMI, diabetes duration, biobank year, HbA1c, fasting glucose, total cholesterol, HDL and LDL cholesterol, cholesterol ratio, triglycerides and eGFR were used as variables.

\section*{RESULTS}

Cohort characteristics are shown in Table 1 and Supplemental Tables 1-5. Differences between cohorts in for instance diabetes duration and glucose-lowering medication use were accounted for by using random effects meta-analyses. A schematic overview of the study and its main results is shown in Figure 1.

\subsection*{Association between metabolomic measures and HbA1c}

Using a linear regression model including age, sex and use of statins or other lipid lowering medication as covariates, we found significant associations between metabolomic measures and HbA1c levels in all four cohorts. In the meta-analyses, 81 measures were significantly associated with HbA1c levels after multiple testing correction (Model 1, Supplemental Table 7). The most significant association was observed with the Fischer ratio (BCAA/aromatic amino acids; $\beta$=0.05±0.00, $P$=4.6x10^{-42}). After further adjustment for BMI, glucose-lowering drug use, insulin use and diabetes duration 75 measures were significant (67\% overlap, Model 2, Supplemental Table 7).

We next tested in a logistic regression model whether metabolomic measures were also associated with the inability to achieve the glycemic target of an HbA1c below 53 mmol/mol. Twenty-six measures (8 metabolites; 18 others) belonging to various metabolomic classes were significantly associated. The most significant association was found for glutamine (OR=0.66 (95\%CI 0.61;0.73), $P$=7.6x10^{-19}, Table 2, Supplemental Table 8). Most of these 26 were also significant in the linear regression model mentioned above (21/26) but not always in the extended model 2 (15/26).

In a sensitivity analysis, exclusion of people with less than one year duration of diabetes and those only treated with a diet did not materially affect the results. This suggests that the observed associations were not driven by those with newly discovered or mild/screen detected diabetes. We also did not observe major differences between men and women (data not shown).

We also tested whether use of different glucose-lowering drugs affected the observed associations. For this we first evaluated whether the different treatment regimens in patients were associated with the metabolomic measures as compared to those who did not use any type of glucose-lowering drug. Supplemental Table 9 shows the results of the meta-analyses for the age, sex, BMI, statin use and other lipid lowering medication adjusted model (5 metabolites; 21 others significant.). With addition of diabetes duration, HbA1c, fasting glucose and eGFR into the model, 31 measures (3 metabolites; 28 others) remained significantly different in one or more of the treatment groups compared to those who did not use any type of glucose-lowering drug (Table 3, Supplemental Table 10). The metabolomic measures represent various categories including, amino-acids, phospholipids,
apolipoproteins, cholesterol and various lipoprotein subclasses. The strongest association was observed for ApoA1 and metf + SU dual therapy ($\beta$=-0.148 (0.026); $P=1.7 \times 10^{-8}$)

In treatment group stratified meta-analyses for the 26 measures identified in the logistic regression model for insufficient glycemic control we found only modest evidence for an effect of medication on these associations (Supplemental Table 11). Only those in the small SU monotherapy or “other” groups sometimes show aberrant responses. However, in the interaction analyses of treatment_group*metabolite there were no significant associations (all $p \geq 8.5 \times 10^{-3}$, data not shown). Altogether, these results imply that, in general, the major glucose lowering drugs had little effect on the observed associations between metabolomic measures and HbA1c.

**Association between metabolomic measures and initiation of insulin therapy**

Diabetes progression was defined as initiation of insulin therapy during follow-up. Because the exact starting date of insulin therapy was not always known we used logistic regression models for the prospective studies, however, cox regression in the DCS cohort showed highly similar results (data not shown). In a meta-analysis of the two cohorts with prospective data we tested whether the 26 metabolomic measures identified above were also associated with initiation of insulin therapy during seven year follow-up (n=698, 123 cases). Out of the 26 metabolomic measures, eleven were significantly associated with insulin initiation (model 1, Table 4) compared to 15 of the remaining 136 metabolites ($P$ for enrichment=3.8x10$^{-4}$). The most significant association was again with ApoA1 (OR=0.52 (95%CI=0.40;0.67), $P=7.97 \times 10^{-7}$). Further adjustment for age, sex, BMI, statin use, other lipid lowering use, diabetes duration, SU use, metformin use, other diabetes medication use, HbA1c and fasting glucose reduced the number of significant associations to six (model 2, Table 4). The most significant association was with M-HDL-CE (OR=0.54 (95%CI=0.42;0.71); $P=4.5 \times 10^{-6}$).

Independent replication (Rotterdam study, 40 cases/355 controls, 5 years follow-up) showed that five of these also showed directionally consistent evidence for nominal association ($P \leq 0.05$) in the smaller replication study (Supplemental Table 12).

It is known that for various reasons people who should use insulin because of prolonged elevated HbA1c levels are not using this drug and therefore we performed some sensitivity analyses in the DCS study. We first calculated propensity scores for using insulin at baseline based on the baseline characteristics of participants either using or not using insulin. Adding these propensity scores to the regression models did not largely impact the results. Next, we re-classified as insulin initiators 11 persons who had elevated HbA1c levels on at least two of the yearly follow-up visits (HbA1c>64). This analysis did not materially affect our results nor did the exclusion of these persons from our analyses (data not shown).

**DISCUSSION**

This study has several main findings (Figure 1). First, in cross-sectional analyses we showed that 26 measures were associated with insufficient glycemic control, which was largely independent of the effects of glucose-lowering medications. Second, we identified 31 measures that differ between individuals treated with different glucose-lowering drugs. Thirdly, we showed in prospective analyses that five of the 26 measures associated with insufficient glycemic control were also associated with insulin initiation during follow-up.

**Metabolomic measures and glycemic control**

Increased levels of BCAAs, as observed in our study, were previously shown associated with insulin resistance and risk of prevalent and incident diabetes(4,21). We now showed that this association extends to glycemic control in people with type 2 diabetes. Glutamine, ranked 1$^\text{st}$ in our analyses, is known to be associated with insulin sensitivity and reduced diabetes risk, which is in line with our observed inverse correlation(6,22,23). Furthermore, we showed...
positive associations with several markers of fatty acid composition and saturation and respectively positive and negative associations with concentrations of various VLDL, LDL and HDL subclasses. Previous studies have shown that these measures are associated with various degrees of glucose tolerance, insulin resistance and/or diabetes risk(24-27). In general, our data suggest that metabolomic measures that were previously shown to be associated with type 2 diabetes risk are also associated with worse glycemic control.

Most of the significant associations with insufficient glycemic control are only marginally influenced by different diabetes drugs in the stratified analysis. In all treatment groups insufficient glycemic control is, for instance, positively associated with the Fischer ratio and most BCAAs, however, in the SU group there is no or even an inverse association (Supplemental Figure 2). For most of the fatty acids and lipoprotein subclasses we note a similar picture in the SU treatment group, associations are less pronounced or the reverse of what is observed for the other treatment groups. It seems that those in the “other” group in general show stronger but directionally consistent associations. However, due to small numbers in the both these groups differences are not statistically significant and thus require further studies. Metabolites such as glutamine and lactate showed much more similar associations in all treatment groups suggesting a more generalized association of these metabolites with glycemic control. The differences in associations observed in the various treatment groups were not explained by differences in glycemic control, obesity or diabetes duration. It is therefore reasonable to assume that they were related to differences in the working mechanism of these drugs targeting either predominantly beta-cell function or insulin action and further studies are needed to investigate this in detail.

**Diabetes treatment and metabolomic measures**

To our best knowledge we are the first to show the association of different types of glucose-lowering drugs with various metabolites and or metabolomic measures in a large series of type 2 diabetes patients treated according to routine clinical care. Our results suggest that the observed differences were not strongly driven by differences in glycemic control or disease duration between groups. In general it seemed that the direction and size of the effects were comparable between treatment groups, although not always reaching formal levels of significance which is likely attributable to small number of patients in some subgroups. For example, it was previously shown that, among others, the phospholipid content of very large HDL (XL-HDL-PL) was lowered by metformin treatment (8,28). Our data suggest this was not specific for metformin, but rather universal for most or all glucose-lowering drugs (Supplemental Figure 3). Furthermore, individuals in most treatment groups except the “other” glucose-lowering drug group had lower levels of HDL subclasses compared to those without glucose-lowering treatment (Supplemental Figure 3). As thiazolidinediones are included in this “other” group this might relate to known HDL cholesterol increasing effects of these drugs(29).

In addition to the generic effects of glucose-lowering drugs we also observed drug-specific associations. For instance, increased alanine levels in relation to metformin therapy have been reported before(8,30). Here we show that compared to treatment naive patients, alanine levels are most strongly increased in metformin mono or dual therapy with SU groups. BCAAs (Val, Leu and Ile) and the Fischer ratio (ratio of BCAA over aromatic amino acids) were increased in those treated with metformin, but like alanine not or much less in those treated with SU or other glucose-lowering drugs. This might be related to differences in the working mechanism of these drugs.

**Metabolomic measures and initiation of insulin therapy**

For patients not able to achieve good glycemic control on oral glucose-lowering drugs, initiation of insulin therapy is often the final treatment option. Type 2 diabetes patients who
require insulin therapy have often been treated for years with oral glucose-lowering drugs without achieving sufficient glycemic control. This leads to an unwanted and prolonged exposure to high glucose levels and increased risk of developing diabetes related complications(2). Early indicators of treatment failure and rapid progression towards insulin therapy are thus urgently needed. We show that a subset of the metabolomic measures that were cross-sectionally associated with insufficient glycemic control, were also associated with progression towards insulin therapy during follow-up.

Interestingly, the BCAAs whilst shown to be causally related to development of T2D(21), were not associated with progression to insulin use. Also other metabolites associated with insufficient glycemic control in our study were not significantly associated with incident insulin use. Our data show that high levels of ApoA1 and M-HDL lipoprotein subclasses were associated with an almost two-fold reduced risk of incident insulin use. These findings refine the results of previous studies that identified low HDL-cholesterol as a risk factor for initiation of insulin therapy(31) and progression of glycemia in type 2 diabetes (32). Insulin resistance impairs VLDL metabolism by, 1) reducing the LPL-mediated generation of VLDL-remnants and, 2) simultaneously increasing the flux of adipose tissue derived FA to the liver. Both processes lead to increased production of VLDL. The increased abundance of VLDL drives CETP mediated transfer of CE from HDL to VLDL, leading to a reduction in HDL-levels. Increased plasma VLDL and decreased HDL are characteristic of the so-called diabetic dyslipidemia (reviewed in Goldberg(33)). Diabetic dyslipidemia represents a more advanced stage of insulin resistance and may thus identify those individuals that are more likely to progress towards insulin use. Alternatively, ApoA1 and HDL have also been suggested to modulate pancreatic β-cell function via incretin-like effects(34). Further detailed studies are needed to clarify this in detail.

Strengths of this study are the use of large numbers of patients, incorporation of at least three independent cohorts in all main analyses, the use of a targeted metabolomics platform that is already approved for clinical care and the use of stringent corrections for multiple hypothesis testing to reduce the chance of false positive findings. Limitations are the use of cross-sectional metabolomics data. Given this design we could not study the within subject effects on the metabolomic measures after initiation of glucose-lowering treatment in treatment-naïve individuals. Another limitation is the relatively small number of subjects in some of the treatment groups and in the prospective studies limiting the power to detect more modest associations. The use of logistic regression models for the prospective studies is a limitation, however, cox regression in the DCS cohort showed highly similar results. In addition, although we were able to show that several metabolomic measures were associated with incident insulin use further studies using for instance lasso regression are warranted to find the best combination of clinical and metabolomic predictors of initiation of insulin therapy. However, this is beyond the scope of this manuscript. Finally, the metabolomics platform we used targets a relatively small and correlated number of metabolomic measures and is thus not representative of the whole metabolome. Because of the known correlation structure between the measures, signals are not all independent but rather provide detailed information on the underlying biology. Further detailed metabolomic and lipidomic studies using specialized platforms allowing for more comprehensive and detailed analyses are needed to elucidate the underlying biology.

In conclusion, this is the first study to show that blood metabolomic measures are associated with glycemic control. We also show that, although the blood metabolome shows differences between patients who are on different types of glucose-lowering medication, glucose-lowering medication did not materially affect the associations with glycemic control. Finally, we show that baseline levels of the metabolomic measures that were associated with insufficient glycemic control were also prospectively associated with initiation of insulin
therapy. This shows that metabolomic profiles may be useful for the identification of those at increased risk of treatment failure on non-insulin therapies.

Acknowledgements
The authors would like to thank all participants in the studies for their cooperation.

Corresponding author: LM ‘t Hart, PhD, Leiden University Medical Center, Department of Cell and Chemical Biology, Albinusdreef 2, 2333ZA Leiden, the Netherlands, T: 0031 71 5269796, E: lmthart@lumc.nl

Funding
This work was performed within the framework of the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) Metabolomics Consortium funded by BBMRI-NL, a research infrastructure financed by the Dutch government (NWO, grant nr 184.021.007 and 184033111). It was furthermore funded by ZonMW Priority Medicines Elderly (grant 113102006). CODAM was supported by grants from the Netherlands Organization for Scientific Research (940–35–034), the Dutch Diabetes Research Foundation (98.901), the Parel Neer Initiative (PSI). PSI is part of and is funded by the Dutch Federation of University Medical Centres and from 2007 to 2011 received initial funding from the Dutch Government. The work of NV was supported through a grant from the Maastricht University Medical Center+. DM-K is supported by the Dutch Science Organization (ZonMW VENI Grant 916.14.023). The metabolomics measurements in the NEO study were funded by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON2014-02 ENERGISE). The Maastricht Study was supported by the European Regional Development Fund via OP-Zuid, the Province of Limburg, the Dutch Ministry of Economic Affairs (grant 31O.041), Stichting De Weijerhorst (Maastricht, the Netherlands), the Pearl String Initiative Diabetes (Amsterdam, the Netherlands), CARIM School for Cardiovascular Diseases (Maastricht, the Netherlands), Stichting Annadal (Maastricht, the Netherlands), Health Foundation Limburg (Maastricht, the Netherlands) and by unrestricted grants from Janssen-Cilag B.V. (Tilburg, the Netherlands), Novo Nordisk Farma B.V. (Alphen aan den Rijn, the Netherlands) and Sanofi-Aventis Netherlands B.V. (Gouda, the Netherlands). The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The data presented in this manuscript have been presented before as an abstract at the annual meeting of the EASD (Lisbon, Portugal Sept 2017).

Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) Metabolomics Consortium funded by BBMRI-NL, a research infrastructure financed by the Dutch government, 184021007 + 184033111, Leen M t’ Hart; ZonMW Priority Medicines Elderly, Leen M t’ Hart; NOW, 940–35–034, Marleen van Greevenbroek; Dutch Diabetes Research Foundation, Marleen van Greevenbroek; Maastricht University Medical Center, Nicole Vogelzangs; ZonMW, 916.14.023, Dennis O Mook-Kanamori; Dutch Heart Foundation, CVON2014-02 ENERGISE, Ko Willems van Dijk; European Regional Development Fund, Coen D.A. Stehouwer; Dutch Ministry of Economic Affairs, 31O.041, Coen D.A. Stehouwer; Stichting De Weijerhorst, Coen D.A. Stehouwer; CARIM, Coen D.A. Stehouwer; Stichting Annadal, Coen D.A. Stehouwer; Health Foundation Limburg, Coen D.A. Stehouwer; Janssen-Cilag B.V., Coen D.A. Stehouwer; Novo Nordisk Farma B.V., Coen D.A. Stehouwer; Sanofi-Aventis Netherlands B.V., Coen D.A. Stehouwer

Author contribution
LMtH, JMD, GN, CJHKvdK, IA and MvG contributed to the conception and design of the study. LMtH, NV, DM-K, AB, JN and TM researched the data. All authors contributed to the acquisition and/or interpretation of the data. LMtH wrote the manuscript. All authors critically read the manuscript, suggested revisions and approved the final version of the manuscript.

Disclosure Summary:
The authors have nothing to disclose.

References


Figure 1. Schematic overview of the study design and main results.

Table 1. Baseline clinical characteristics of the study samples

<table>
<thead>
<tr>
<th></th>
<th>DCS</th>
<th>Maastricht</th>
<th>CODAM</th>
<th>NEO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Random sample (n=750)</td>
<td>Selected sample (n=245)</td>
<td>n=134</td>
<td>n=664</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62.7 ± 10.2</td>
<td>63.5 ± 10.9</td>
<td>62.8 ± 6.3</td>
<td>61.1 ± 6.3</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.7 ± 5.5</td>
<td>30.3 ± 5.4</td>
<td>29.9 ± 4.9</td>
<td>30.0 ± 4.3</td>
</tr>
<tr>
<td>HbA1c (mmol/mol)</td>
<td>46 (43-53)</td>
<td>53 (47-62)</td>
<td>50 (45-56)</td>
<td>50 (43-57)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>6.4 (6.1-7.0)</td>
<td>7.0 (6.4-7.8)</td>
<td>6.7 (6.3-7.3)</td>
<td>6.7 (6.1-7.4)</td>
</tr>
<tr>
<td>HbA1c &gt;53 (mmol/mol)</td>
<td>158 (21)</td>
<td>120 (49)</td>
<td>275 (32)</td>
<td>47 (35)</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>6.3 ± 4.7</td>
<td>7.6 ± 4.8</td>
<td>7.3 ± 6.8</td>
<td>3.2 ± 5.2</td>
</tr>
<tr>
<td>Diabetes duration &lt;1 year (n)</td>
<td>36 (5)</td>
<td>8 (3)</td>
<td>134 (17)</td>
<td>77 (58)</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>56.9 ± 10.1</td>
<td>56.4 ± 10.6</td>
<td>55.6 ± 9.1</td>
<td>57.9 ± 7.1</td>
</tr>
<tr>
<td>Statin use</td>
<td>524 (70)</td>
<td>162 (66)</td>
<td>627 (74)</td>
<td>31 (23)</td>
</tr>
<tr>
<td>Other lipid lowering drug use</td>
<td>22 (0.3)</td>
<td>10 (0.4)</td>
<td>54 (6.4)</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td>No medication</td>
<td>91 (12)</td>
<td>9 (4)</td>
<td>189 (22)</td>
<td>70 (52)</td>
</tr>
<tr>
<td>Metformin</td>
<td>275 (37)</td>
<td>40 (16)</td>
<td>264 (31)</td>
<td>7 (5)</td>
</tr>
<tr>
<td>Metf+SU</td>
<td>142 (19)</td>
<td>56 (23)</td>
<td>136 (16)</td>
<td>16 (12)</td>
</tr>
<tr>
<td>SU</td>
<td>50 (7)</td>
<td>19 (8)</td>
<td>20 (2)</td>
<td>28 (21)</td>
</tr>
<tr>
<td>Insulin</td>
<td>154 (21)</td>
<td>109 (45)</td>
<td>175 (21)</td>
<td>11 (8)</td>
</tr>
<tr>
<td>Other</td>
<td>38 (5)</td>
<td>12 (5)</td>
<td>63 (7)</td>
<td>2 (2)</td>
</tr>
</tbody>
</table>

Date represent mean ± SD, median (IQR) or n (%). The DCS sample consists of a random sample of 750 and a total sample in which 245 subjects with diabetic complications and or not able to reach the clinical target of HbA1c where added to the random sample to increase power in case-control analyses.

Table 2. Metabolomic measures significantly associated with insufficient glycemic control (HbA1c>53 mmol/mol).

<table>
<thead>
<tr>
<th>Measure</th>
<th>Model 1</th>
<th>Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Gln</td>
<td>0.66</td>
<td>(0.61,0.73)</td>
</tr>
<tr>
<td>Ile</td>
<td>1.41</td>
<td>(1.26,1.57)</td>
</tr>
<tr>
<td>Leu</td>
<td>1.44</td>
<td>(1.31,1.59)</td>
</tr>
<tr>
<td>Measure</td>
<td>OR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>---</td>
</tr>
<tr>
<td>UnsatDeg</td>
<td>0.80 (0.73;0.87)</td>
<td>8.08×10^-10</td>
</tr>
<tr>
<td>Fw3-F FA</td>
<td>0.83 (0.76;0.91)</td>
<td>6.22×10^-10</td>
</tr>
<tr>
<td>PUFA-F A</td>
<td>0.83 (0.77;0.91)</td>
<td>3.45×10^-10</td>
</tr>
<tr>
<td>SFA-F A</td>
<td>1.23 (1.10;1.36)</td>
<td>2.08×10^-10</td>
</tr>
<tr>
<td>LDL-TG</td>
<td>1.26 (1.15;1.38)</td>
<td>4.61×10^-10</td>
</tr>
<tr>
<td>ApoA1</td>
<td>0.80 (0.71;0.90)</td>
<td>1.54×10^-9</td>
</tr>
<tr>
<td>XS-VLDL-TG</td>
<td>1.26 (1.13;1.40)</td>
<td>2.47×10^-10</td>
</tr>
<tr>
<td>IDL-TG</td>
<td>1.27 (1.16;1.38)</td>
<td>1.57×10^-10</td>
</tr>
<tr>
<td>LDL-TG</td>
<td>1.25 (1.14;1.38)</td>
<td>4.46×10^-10</td>
</tr>
<tr>
<td>M-LDL-TG</td>
<td>1.21 (1.11;1.33)</td>
<td>2.33×10^-10</td>
</tr>
<tr>
<td>S-LDL-TG</td>
<td>1.19 (1.09;1.30)</td>
<td>6.95×10^-10</td>
</tr>
<tr>
<td>XL-HDL-FC</td>
<td>0.81 (0.73;0.90)</td>
<td>1.01×10^-10</td>
</tr>
<tr>
<td>M-HDL-P</td>
<td>0.83 (0.75;0.91)</td>
<td>8.86×10^-10</td>
</tr>
<tr>
<td>M-HDL-L</td>
<td>0.82 (0.75;0.90)</td>
<td>3.49×10^-10</td>
</tr>
<tr>
<td>M-HDL-C</td>
<td>0.79 (0.70;0.89)</td>
<td>6.70×10^-10</td>
</tr>
<tr>
<td>M-HDL-CE</td>
<td>0.78 (0.70;0.88)</td>
<td>5.05×10^-10</td>
</tr>
<tr>
<td>M-HDL-FC</td>
<td>0.80 (0.72;0.90)</td>
<td>2.19×10^-10</td>
</tr>
<tr>
<td>S-HDL-TG</td>
<td>1.27 (1.15;1.40)</td>
<td>4.47×10^-10</td>
</tr>
</tbody>
</table>

Results represent odds ratio and 95% confidence interval from logistic regression analyses for insufficient glycemic control of DCS, Maastricht, CODAM and NEO data. Model 1: adjusted for Age, Sex, Statin use and other lipid lowering medication use. Model 2: adjusted for Age, Sex, Statin use, other lipid lowering use, BMI, diabetes duration, OHA use, insulin use. Bonferroni significant associations (P<3.1×10^-4). Full data for all metabolomic measures is provided in supplemental table 8.
M-HDL-FC | -0.114 (0.057) | -0.171 (0.049) | -0.119 (0.027) | -0.356 (0.148) | -0.048 (0.029)

Data represent Beta (SE) from random effect meta-analyses of DCS. Maastricht and NEO data of metabolomic measures against medication use with adjustment for age, sex, BMI, statin use, other lipid lowering medication, diabetes-duration, HbA1c, Fasting Glucose and eGFR. Treatment naive patients were used as a reference (n=611) in separate analyses for each treatment group. * Bonferroni significant associations (\(P \leq 3.1 \times 10^{-4}\)).

Table 4. Metabolomic measures significantly associated with insulin initiation during follow-up.

<table>
<thead>
<tr>
<th>Metabolites</th>
<th>Model 1 OR (95% CI)</th>
<th>P</th>
<th>Model 2 OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glu</td>
<td>0.86 (0.701, 1.07)</td>
<td>1.14</td>
<td>(0.681, 1.90)</td>
<td>6.30 \times 10^{-1}</td>
</tr>
<tr>
<td>Ile</td>
<td>1.58 (1.22, 2.04)</td>
<td>1.25</td>
<td>(0.76, 2.06)</td>
<td>3.72 \times 10^{-2}</td>
</tr>
<tr>
<td>Leu</td>
<td>1.54 (1.23, 1.93)</td>
<td>1.22</td>
<td>(0.94, 1.58)</td>
<td>1.26 \times 10^{-1}</td>
</tr>
<tr>
<td>Val</td>
<td>1.63 (1.31, 2.03)</td>
<td>1.20</td>
<td>(0.75, 1.94)</td>
<td>4.50 \times 10^{-2}</td>
</tr>
<tr>
<td>BCAA</td>
<td>1.72 (1.37, 2.13)</td>
<td>1.25</td>
<td>(0.74, 2.12)</td>
<td>4.10 \times 10^{-1}</td>
</tr>
<tr>
<td>Fischer Ratio</td>
<td>1.79 (1.42, 2.26)</td>
<td>1.40</td>
<td>(1.08, 1.81)</td>
<td>1.22 \times 10^{-2}</td>
</tr>
<tr>
<td>bOHBut</td>
<td>1.03 (0.84, 1.26)</td>
<td>0.81</td>
<td>(0.61, 1.08)</td>
<td>1.45 \times 10^{-1}</td>
</tr>
<tr>
<td>Lac</td>
<td>1.40 (1.16, 1.70)</td>
<td>1.06</td>
<td>(0.66, 1.69)</td>
<td>8.10 \times 10^{-1}</td>
</tr>
</tbody>
</table>

Other metabolomic measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnsatDeg</td>
<td>0.73 (0.58, 0.92)</td>
<td>0.78</td>
<td>(0.61, 0.98)</td>
<td>3.45 \times 10^{-2}</td>
</tr>
<tr>
<td>FAw3-FA</td>
<td>0.74 (0.52, 1.05)</td>
<td>0.58</td>
<td>(0.21, 1.63)</td>
<td>3.01 \times 10^{-1}</td>
</tr>
<tr>
<td>PUFA-FA</td>
<td>0.84 (0.56, 1.27)</td>
<td>0.88</td>
<td>(0.70, 1.31)</td>
<td>2.69 \times 10^{-1}</td>
</tr>
<tr>
<td>SFA-FA</td>
<td>1.22 (0.99, 1.50)</td>
<td>1.10</td>
<td>(0.88, 1.31)</td>
<td>4.15 \times 10^{-1}</td>
</tr>
<tr>
<td>LDL-TG</td>
<td>1.01 (0.50, 1.70)</td>
<td>1.03</td>
<td>(0.82, 1.30)</td>
<td>7.90 \times 10^{-1}</td>
</tr>
<tr>
<td>ApoA1</td>
<td>0.52 (0.40, 0.67)</td>
<td>0.53*</td>
<td>(0.39, 0.70)</td>
<td>3.31 \times 10^{-1}</td>
</tr>
<tr>
<td>Xs-VLDL-TG</td>
<td>1.18 (0.73, 1.90)</td>
<td>1.25</td>
<td>(1.02, 1.53)</td>
<td>3.47 \times 10^{-2}</td>
</tr>
<tr>
<td>IDL-TG</td>
<td>1.12 (0.67, 1.90)</td>
<td>1.21</td>
<td>(0.97, 1.50)</td>
<td>8.95 \times 10^{-1}</td>
</tr>
<tr>
<td>L-LDL-TG</td>
<td>1.01 (0.60, 1.70)</td>
<td>1.05</td>
<td>(0.84, 1.33)</td>
<td>6.68 \times 10^{-1}</td>
</tr>
<tr>
<td>M-LDL-TG</td>
<td>0.95 (0.56, 1.62)</td>
<td>0.98</td>
<td>(0.78, 1.23)</td>
<td>8.53 \times 10^{-1}</td>
</tr>
<tr>
<td>S-LDL-TG</td>
<td>1.06 (0.62, 1.81)</td>
<td>1.12</td>
<td>(0.91, 1.38)</td>
<td>3.02 \times 10^{-1}</td>
</tr>
<tr>
<td>XL-HDL-FC</td>
<td>0.59 (0.46, 0.75)</td>
<td>0.64</td>
<td>(0.49, 0.83)</td>
<td>6.55 \times 10^{-1}</td>
</tr>
<tr>
<td>M-HDL-P</td>
<td>0.56 (0.44, 0.72)</td>
<td>0.54*</td>
<td>(0.41, 0.72)</td>
<td>1.52 \times 10^{-1}</td>
</tr>
<tr>
<td>M-HDL-L</td>
<td>0.57 (0.44, 0.72)</td>
<td>0.55*</td>
<td>(0.42, 0.72)</td>
<td>1.62 \times 10^{-1}</td>
</tr>
<tr>
<td>M-HDL-C</td>
<td>0.56 (0.44, 0.70)</td>
<td>0.54*</td>
<td>(0.41, 0.70)</td>
<td>4.67 \times 10^{-1}</td>
</tr>
<tr>
<td>M-HDL-Ce</td>
<td>0.56 (0.44, 0.71)</td>
<td>0.54*</td>
<td>(0.42, 0.71)</td>
<td>4.46 \times 10^{-1}</td>
</tr>
<tr>
<td>M-HDL-FC</td>
<td>0.55 (0.43, 0.70)</td>
<td>0.53</td>
<td>(0.40, 0.70)</td>
<td>1.01 \times 10^{-1}</td>
</tr>
<tr>
<td>S-HDL-TG</td>
<td>1.40 (1.00, 1.95)</td>
<td>1.57</td>
<td>(1.01, 1.69)</td>
<td>4.21 \times 10^{-1}</td>
</tr>
</tbody>
</table>

Results represent odds ratio and 95% confidence interval from fixed effect meta-analyses of the logistic regression analyses for insulin initiation in DCS and CODAM prospective data. Model 1: Age, Sex, Statin-use and other lipid lowering medication use. Model 2: Age, Sex, Statin use, other lipid lowering use, BMI, diabetes duration, SU use, metformin use, other diabetes med use, HbA1c and fasting glucose. Bonferroni significant associations (\(P<3.1 \times 10^{-4}\)), * \(P<0.05\) in the replication study (Supplemental table 12).
### Glycemic control

- **DCS, Maastricht, CODAM, NEO N=2631**

### Cross sectional studies

- **HbA1c >53 mmol/mol (Y/N)**
  - 26 measures (**P≤3.1x10^{-4}**)
  - Tables 2, S9

### Prospective studies

- **Diabetes progression**
  - DCS, CODAM
  - N=123 cases, 595 controls
  - **HbA1c >53 mmol/mol (Y/N)**
  - 6/26 measures (**P≤3.1x10^{-4}**)
  - Table S7

- **Initiation of insulin therapy (Y/N)**
  - 6/26 measures (**P≤3.1x10^{-4}**)
  - Table 4

### Replication study (40 cases/355 controls)

- **HbA1c >53 mmol/mol (Y/N)**
  - 5/6 measures (**P≤0.05**)
  - Table S12

### Glucose-lowering drugs

- **DCS, Maastricht, NEO N=2256**

- **Glycemic control**
  - 81 measures (**P≤3.1x10^{-4}**)
  - Table S7

- **Glucose-lowering drug stratified (6 groups)**
  - 31 measures (**P≤3.1x10^{-4}**)
  - Tables 3, S9, S10

- **Metabolic measures**
  - 31 measures (**P≤3.1x10^{-4}**)
  - Tables 3, S9, S10